These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34618894)

  • 1. The Future of Somatostatin Receptor Ligands in Acromegaly.
    Gadelha MR; Wildemberg LE; Kasuki L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):297-308. PubMed ID: 34618894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A; Melmed S
    Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.
    Fleseriu M
    Pituitary; 2011 Jun; 14(2):184-93. PubMed ID: 21161602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide in the Personalized Treatment of Acromegaly.
    Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
    Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
    Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
    J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
    Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
    Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acromegaly with oral octreotide.
    Remba-Shapiro I; Nachtigall LB
    Best Pract Res Clin Endocrinol Metab; 2024 Jul; 38(4):101888. PubMed ID: 38443224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
    Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
    Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to Position Pasireotide LAR Treatment in Acromegaly.
    Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs).
    Brunetti A; Antonini S; Saladino A; Lavezzi E; Zampetti B; Cozzi R
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice.
    Geer EB; Sisco J; Adelman DT; Ludlam WH; Haviv A; Liu S; Mathias SD; Gelbaum D; Shi L
    BMC Endocr Disord; 2020 Jul; 20(1):117. PubMed ID: 32736547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use.
    Fleseriu M; Nachtigall LB; Samson SL; Melmed S
    Expert Rev Endocrinol Metab; 2024 Jul; 19(4):367-375. PubMed ID: 38842362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide: a novel treatment for patients with acromegaly.
    Cuevas-Ramos D; Fleseriu M
    Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
    Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
    BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
    Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
    J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
    Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
    Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
    Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
    J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
    Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
    Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
    Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.